Fractyl Health, Inc. Common Stock
Here’s whether Fractyl Health, Inc. Common Stock (GUTS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: above the 50-day MA (medium-term momentum positive). Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-1.55% over 10 days); weak 1-year return of -21.2%; 3-month momentum negative (-14.2%). Currently 68.1% off its 52-week high. Score: -4/7.
GUTS is trading below its 200-day MA ($0.99) — a key warning sign the longer-term trend is under pressure. An RSI of 65.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -21.2% compares to +20.5% for SPY (trailed the market by 41.7%). The current 68.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.